International Clinical Psychopharmacology最新文献_第5页

Same outcome, different walls: rethinking comparisons in prison suicide research. 相同的结果，不同的墙：重新思考监狱自杀研究中的比较。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-11-26 DOI: 10.1097/YIC.0000000000000601

Raffaella Calati, Franca Crippa, Stefano Tambuzzi, Fabio Madeddu, Riccardo Zoja, Guendalina Gentile

引用次数: 0

Effects of transcranial direct current stimulation (tDCS) at different cortical targets on cognition in obsessive-compulsive disorder (OCD): an exploratory analysis. 经颅直流电刺激（tDCS）对强迫症（OCD）认知的影响：探索性分析。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-04-04 DOI: 10.1097/YIC.0000000000000589

Luca Pellegrini, Eduardo Cinosi, David Wellsted, Megan Smith, Amanda Busby, Natalie Hall, Umberto Albert, Ibrahim Aslan, Matt Garner, Samuel R Chamberlain, Trevor W Robbins, David S Baldwin, Naomi A Fineberg

{"title":"Effects of transcranial direct current stimulation (tDCS) at different cortical targets on cognition in obsessive-compulsive disorder (OCD): an exploratory analysis.","authors":"Luca Pellegrini, Eduardo Cinosi, David Wellsted, Megan Smith, Amanda Busby, Natalie Hall, Umberto Albert, Ibrahim Aslan, Matt Garner, Samuel R Chamberlain, Trevor W Robbins, David S Baldwin, Naomi A Fineberg","doi":"10.1097/YIC.0000000000000589","DOIUrl":"10.1097/YIC.0000000000000589","url":null,"abstract":"Transcranial direct current stimulation (tDCS) holds promise as a treatment for obsessive-compulsive disorder (OCD). Patients with OCD show impairment in specific domains of cognitive flexibility and response inhibition. We previously reported that tDCS produced a positive clinical effect on OCD symptoms. Here, we report a secondary analysis of neurocognitive data. In this randomized, double-blind, sham-controlled, crossover, multicenter feasibility study, adults with a diagnosis of OCD according to the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) received three courses of clinic-based tDCS, targeting the left orbitofrontal cortex (L-OFC), bilateral supplementary motor area (SMA), and sham, randomly allocated and delivered in counterbalanced order. Cognitive assessments were conducted before and 2-h after the first stimulation in each arm. Nineteen adults were recruited. tDCS of both the L-OFC and SMA significantly improved cognitive inflexibility, while sham treatment did not (paired-sample t test, baseline vs. 2-h after stimulation). No significant effect of tDCS was found for motor impulsivity (stop-signal reaction time) in any of the three arms. In a small sample of patients with OCD, a single administration of tDCS to the L-OFC and SMA produced a rapid improvement in cognitive inflexibility but not in motor impulsivity. A definitive randomized, controlled trial of tDCS targeting both the OFC and SMA, including cognitive markers, is indicated.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"43-51"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12655887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcranial direct current stimulation and cognitive modifiability in obsessive compulsive disorder: a reaction to recent findings by Pellegrini et al. 经颅直流电刺激和强迫症的认知改变：对佩莱格里尼等人最近发现的反应。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-11-26 DOI: 10.1097/YIC.0000000000000600

Rodolfo Leuzzi, Bernardo Dell'Osso

引用次数: 0

Comment on 'Suicide in prison in the North of Italy (1993-2022): a case control study examining differences between suicides inside and outside prison'. 评论“意大利北部监狱自杀（1993-2022）：一项调查监狱内外自杀差异的病例对照研究”

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-11-26 DOI: 10.1097/YIC.0000000000000602

José L Rodríguez-Hernández, Alvaro J Idrovo

引用次数: 0

Beyond symptom reduction: targeting cognitive deficits in obsessive-compulsive disorder treatment. 超越症状减轻：强迫症治疗中的认知缺陷。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-11-26 DOI: 10.1097/YIC.0000000000000603

Sam Rashkovich, Ganeev Singh, Eric Hollander

引用次数: 0

Immediate-release vs. prolonged-release lithium formulations in bipolar disorder: a 2-year comparative study. 双相情感障碍的速释与缓释锂制剂：一项为期2年的比较研究。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-02-19 DOI: 10.1097/YIC.0000000000000584

Margherita Barbuti, Martina Moriconi, Daria Bartolini, Ugo De Rosa, Camilla Elefante, Elisa Schiavi, Giulio Perugi

{"title":"Immediate-release vs. prolonged-release lithium formulations in bipolar disorder: a 2-year comparative study.","authors":"Margherita Barbuti, Martina Moriconi, Daria Bartolini, Ugo De Rosa, Camilla Elefante, Elisa Schiavi, Giulio Perugi","doi":"10.1097/YIC.0000000000000584","DOIUrl":"10.1097/YIC.0000000000000584","url":null,"abstract":"The aim of this study is to evaluate the therapeutic outcomes, tolerability, and adherence to immediate-release (IR) and prolonged-release (PR) lithium formulations in patients with bipolar disorder (BD) over a 2-year follow-up. This naturalistic study included 143 BD patients who initiated IR (48%) or PR (52%) lithium treatment at the inpatient and outpatient services of the University Hospital of Pisa. During follow-up, data were collected on side effects, treatment adherence, blood lithium levels, and creatinine and thyroid stimulating hormone concentrations. Clinical efficacy and functioning were assessed using the Clinical Global Impressions for Bipolar Disorder and Functioning Assessment Short Test scales. Approximately 50% of patients completed the 2-year follow-up, with similar dropout rates between the two groups. Both groups showed significant clinical improvement with comparable efficacy. PR lithium, however, was associated with fewer side effects, particularly tremors and gastrointestinal issues, leading to better adherence. Additionally, PR lithium administration resulted in more stable blood lithium levels. Despite its limitations, including the observational design, potential confounders such as concomitant medications, and a high dropout rate, these findings suggest that PR lithium formulations provide similar clinical efficacy to IR formulations but offer superior tolerability. Therefore, PR lithium represents a favorable option for improving adherence, particularly in patients at risk of treatment discontinuation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"25-33"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial. lumateperone辅助治疗重度抑郁症的疗效和安全性：一项随机、双盲、安慰剂对照的临床试验。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-04-09 DOI: 10.1097/YIC.0000000000000590

Zahra Hosseinnia, Mobina Amanollahi, Bahareh Ahli, Fateme Taghavi Zanjani, Fatemeh Amiri, Melika Jameie, Ahmad Shamabadi, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh

{"title":"Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial.","authors":"Zahra Hosseinnia, Mobina Amanollahi, Bahareh Ahli, Fateme Taghavi Zanjani, Fatemeh Amiri, Melika Jameie, Ahmad Shamabadi, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh","doi":"10.1097/YIC.0000000000000590","DOIUrl":"10.1097/YIC.0000000000000590","url":null,"abstract":"This study aimed to investigate the effects of lumateperone as a combination therapy with sertraline in major depressive disorder (MDD). The 8-week, double-blind, placebo-controlled trial was registered with the Iranian Registry of Clinical Trials (registration date: 2022-03-01, registration number: IRCT20090117001556N141). Patients with MDD were randomized to receive either sertraline (100 mg/day) combined with lumateperone (42 mg/day) or sertraline (100 mg/day) with placebo. The Hamilton Depression Rating Scale (HDRS) was used to assess treatment efficacy. Fifty-eight patients with MDD were analyzed (age: 36.91 ± 9.81 and male: 69.0%). The two groups were comparable across baseline sociodemographic and clinical characteristics except for marital status. There was a significant time × treatment interaction on HDRS ( P = 0.027), suggesting greater improvement in depressive symptoms following the lumateperone adjuvant therapy. Compared with the placebo group, a significantly larger proportion of individuals receiving lumateperone experienced an HDRS reduction rate greater than or equal to 50% at weeks 4 (90.0 vs. 60.7%, P = 0.014) and 8 (100 vs. 82.1, P = 0.021). However, the remission rate was not different. No serious adverse events were reported. This study suggests that lumateperone can be considered an effective and safe adjuvant treatment for MDD. Future larger clinical trials with extended follow-up periods are needed to confirm its efficacy for clinical use.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"34-42"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Focus on mood disorders, obsessive-compulsive disorders, and prisoners' treatments. 关注情绪障碍、强迫症和囚犯治疗。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-11-26 DOI: 10.1097/YIC.0000000000000611

Alessandro Serretti

引用次数: 0

Age matters when improving symptoms of anxiety, depression, and sleepiness in patients with obstructive sleep apnea treated with continuous positive airway pressure. 在持续气道正压治疗的阻塞性睡眠呼吸暂停患者中，年龄对焦虑、抑郁和嗜睡症状的改善有影响。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-01-08 DOI: 10.1097/YIC.0000000000000579

Amitoj Singh, Sanket Meghpara, Rijesh Niraula, Lynn Keenan, Lourdes M DelRosso

{"title":"Age matters when improving symptoms of anxiety, depression, and sleepiness in patients with obstructive sleep apnea treated with continuous positive airway pressure.","authors":"Amitoj Singh, Sanket Meghpara, Rijesh Niraula, Lynn Keenan, Lourdes M DelRosso","doi":"10.1097/YIC.0000000000000579","DOIUrl":"10.1097/YIC.0000000000000579","url":null,"abstract":"Obstructive sleep apnea (OSA) is a prevalent sleep disorder linked to significant daytime sleepiness and mood disturbances. Continuous positive airway pressure (CPAP) therapy is the standard treatment for OSA, but its effects on mental health outcomes, are not well understood. This study aimed to evaluate the impact of CPAP on daytime sleepiness, depressive symptoms, and anxiety symptoms while assessing how improvements vary with age. A total of 98 participants diagnosed with OSA were included in this study. Pretreatment and posttreatment scores for daytime sleepiness [Epworth Sleepiness Scale (ESS)], depression [Patient Health Questionnaire (PHQ)], and anxiety [Generalized Anxiety Disorder (GAD)] were collected. Improvements were calculated as the difference between pretreatment and posttreatment scores. Age, sex, ethnicity, apnea-hypopnea index, and CPAP compliance, were analyzed. Significant improvements were observed across all age groups after CPAP treatment: ESS scores improved by a mean of 5.6 points ( P < 0.001), PHQ scores improved by 6.3 points ( P < 0.001), and GAD scores improved by 1.1 points ( P = 0.002). CPAP therapy effectively reduced daytime sleepiness, depression, and anxiety in patients with OSA, with significant age-related differences in outcomes. Younger individuals benefited most from treatment.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"362-366"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review. 在临床实践中区分口服和长效注射抗精神病药物对精神分裂症治疗的影响：一篇叙述性综述。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2025-11-01 Epub Date: 2025-01-22 DOI: 10.1097/YIC.0000000000000578

Andrea Fagiolini, Alessandro Cuomo, Domenico De Berardis, Bernardo Dell'Osso, Maurizio Pompili, Gianluca Serafini

{"title":"Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review.","authors":"Andrea Fagiolini, Alessandro Cuomo, Domenico De Berardis, Bernardo Dell'Osso, Maurizio Pompili, Gianluca Serafini","doi":"10.1097/YIC.0000000000000578","DOIUrl":"10.1097/YIC.0000000000000578","url":null,"abstract":"Schizophrenia is a serious psychiatric condition requiring continuous treatment with antipsychotic medications available in different formulations, including oral antipsychotics (OAPs) and long-acting injectables (LAIs). This narrative review aims to comprehensively outline the advantages and disadvantages of OAPs and LAIs to support clinicians in choosing different formulations based on the presentation of clinical symptoms. An electronic search of the PubMed database was performed in June 2024, and additional articles were retrieved from the references or personal knowledge of the authors. Relevant advantages of OAPs identified in the literature include dosing flexibility, ease of discontinuation, lower cost, autonomy of patient administration, shorter time to steady-state, and wide choice of molecules, including risk of nonadherence, plasma level fluctuations, food and drug interactions, and polypharmacy. LAIs' advantages include improved adherence leading to reduced relapse rates and hospitalizations, patient convenience, and stable drug levels while disadvantages include discomfort of injection, possible stigma, less manageable drug interactions, organization of administration centers, and patient preference possibly contrary to physician preference. When treating schizophrenia, it is critical to consider patients' needs, preferences, and history of medication adherence. Combining patient education with individualized treatment plans may optimize outcomes and improve the quality of life.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"e1-e13"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0